A Case of Minimal Change Disease during Chemotherapy of Bronchogenic Adenocarcinoma.
- Author:
Soo Jeong CHOI
1
;
Chan Kyu KIM
;
Jin Kuk KIM
;
Dae Sik HONG
;
Seung Duk HWANG
;
Kye Won KWON
Author Information
1. Department of Internal Medicine, Soonchunhyang University Medical College, Bucheon, Korea. sd7hwang@schbc.ac.kr
- Publication Type:Case Report
- Keywords:
Minimal change disease;
Bronchogenic adenocarcinoma;
Cisplatin nephrotoxicity;
Acute tubular necrosis
- MeSH:
Adenocarcinoma*;
Biopsy;
Carboplatin;
Cisplatin;
Drug Therapy*;
Edema;
Etoposide;
Female;
Femur;
Humans;
Middle Aged;
Necrosis;
Neoplasm Metastasis;
Nephritis, Interstitial;
Nephrosis, Lipoid*;
Paclitaxel;
Prednisolone;
Proteinuria
- From:Korean Journal of Nephrology
2005;24(2):320-325
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A 60 year-old woman was admitted with generalized edema. The patient had bronchogenic adenocarcinoma which was diagnosed 8 months ago, and treated with 3 cycles of etoposide and cisplatin and 6 cycles of paclitaxel and carboplatin. After completion of chemotherapeutic cycles, massive proteinuria (18, 018 mg/day) developed. Renal biopsy revealed minimal change disease, acute tubular necrosis and chronic interstitial nephritis. In spite of continuous chemotherapy, there was no evidence of remission of cancer lesion on a serial consecutive radiographic study. She quitted continuing chemotherapy, and alternative day high dose of prednisolone was initiated for minimal change disease. Proteinuria was decreased dramatically (180 mg/day) after 2 months, and did not recur during tapering of prednisolone. Although bone metastasis on the right femur was newly detected after 2 months, proteinuria did not develop. We experienced minimal change disease during chemotheraphy of bronchogenic adenocarcinoma, thus we report it with article review.
